Nuvation Bio Shares Rise After First Patient Enrolled in Phase 3 Lung Cancer Drug Trial
MT Newswires Live
Sep 30
Nuvation Bio (NUVB) shares were up more than 13% in recent Tuesday trading after the company said it has enrolled the first patient in its phase 3 trial of Ibtrozi for the treatment of early-stage non-small cell lung cancer.
The phase 3 study will enroll about 180 patients in the US, Canada, Europe, Japan and China with resected ROS1-positive early-stage non-small cell lung cancer who have undergone surgery.
The primary completion date of the study is estimated to be in 2033, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.